The CRISPR and Cas gene market is projected to expand from US$ 2.78 billion in 2022 to US$ 15.10 billion by 2030, reflecting a compound annual growth rate (CAGR) of 23.6% during the period from 2022 to 2030.

This growth is primarily driven by the rising incidence of cancer and genetic disorders, alongside the increasing implementation of CRISPR-based screening methods that target specific genomic sequences. Additionally, the surge in investments from biotechnology firms aimed at developing innovative therapeutics is expected to create further opportunities for the CRISPR and Cas gene market. Nonetheless, challenges such as off-target effects and ethical dilemmas surrounding CRISPR technology may impede market advancement.

CRISPR technology plays a crucial role in detecting mutations across various tumors, identifying modified proteins unique to human cancers. This capability allows for the safe identification of targets for therapeutic intervention. Consequently, the potential for personalized treatment options enabled by CRISPR for chronic conditions like cancer significantly contributes to the market's growth. Furthermore, factors such as increased funding for genomic research, the escalating prevalence of cancer and blood-related diseases, and the commitment of biotechnology companies to develop new treatments are all facilitating market expansion. The growing financial support for genomic studies and initiatives aimed at showcasing CRISPR's effectiveness in genomics are anticipated to introduce new trends in the CRISPR and Cas gene market in the near future. However, the application of CRISPR in drug development and therapeutic practices is constrained by the risk of unintended off-target effects.

In 2022, North America held a significant portion of the global CRISPR and Cas gene market. This region, which includes the US, Canada, and Mexico, is experiencing market growth due to robust research and development activities within the biopharmaceutical sector, as well as the active participation of numerous pharmaceutical companies in creating new therapeutics. For instance, in May 2020, Merck KGaA received FDA approval for two patents related to CRISPR Cas9 gene editing. Additionally, various federal initiatives in the US and Canada are promoting agricultural biotechnology research and the commercial introduction of CRISPR-based agricultural products. Numerous pharmaceutical and seed companies are pursuing growth strategies such as partnerships, acquisitions, and collaborations to enhance the pharmaceutical market and agricultural productivity, further increasing the demand for CRISPR technology in these sectors.

The surge in investments from biotechnology companies focused on novel therapeutics is a key driver of growth in the CRISPR and Cas gene market. Academic institutions and research organizations are actively developing new therapies utilizing genome engineering techniques. For example, in December 2022, a biomedical engineering and computer science assistant professor secured US$ 1.9 million in funding from the National Institutes of Health for genome sequencing research, along with an additional US$ 120,000 from Complete Genomics, a company specializing in human genome sequencing. In January 2021, Pfizer Inc. allocated US$ 120 million to four clinical-stage biotech firms as part of its Pfizer Breakthrough Growth Initiative (PBGI), which aims to invest up to US$ 500 million in biotechnology companies, providing both financial backing and access to Pfizer's scientific expertise to support promising clinical development programs. Such investments are expected to significantly boost the CRISPR and Cas gene market in the forthcoming years.

**Product Type -Based Insights**
The CRISPR and Cas gene market is categorized into products and services. In 2022, the products segment dominated the market share and is projected to achieve a higher CAGR of 23.9% throughout the forecast period.

**Application -Based Insights**
The market is further segmented based on application into biomedical and agricultural sectors. The biomedical segment held the largest market share in 2022 and is expected to register a higher CAGR of 23.8% during the forecast period. CRISPR gene editing technologies are being applied across various life sciences domains. Established delivery methods and the use of nanocarriers have enhanced the effectiveness and precision of this technology. Numerous studies have been conducted to explore the application of this method in modifying human somatic and pluripotent stem cell genomes. Additionally, several companies provide commercial kits and services to assist researchers in utilizing CRISPR gene editing techniques.

Innovative breeding technologies aimed at improving agricultural production have led to better access to nutrient-rich foods globally. For instance, in June 2019, researchers at Cold Spring Harbor Laboratory employed CRISPR/Cas9 technology to induce mutations in a flowering suppressor gene in tomatoes, resulting in accelerated flowering and enhanced compact growth, ultimately leading to earlier yields.

**End User -Based Insights**
The CRISPR and Cas gene market is segmented by end user into biotechnology and pharmaceutical companies, academic and government research institutions, and contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). The biotechnology and pharmaceutical companies segment accounted for the largest market share in 2022 and is projected to exhibit the highest CAGR of 24.2% during the forecast period.

Leading companies are adopting strategies such as expansion, partnerships, new product launches, and customer base acquisitions to capitalize on existing business opportunities.

- In June 2021, QIAGEN launched the QIAprep& CRISPR kit and CRISPR Q-Primer Solutions to assist researchers in analyzing edited genetic material.
- In March 2021, Integrated DNA Technologies (IDT) introduced the rhAmpSeq CRISPR analysis system, providing a comprehensive solution for characterizing and quantifying on- and off-target genome editing outcomes.
- In December 2020, Intellia Therapeutics, Inc. released preclinical data for NTLA-5001, a T-cell therapy candidate targeting Wilms tumor 1 for acute myeloid leukemia treatment.
- In August 2020, Editas Medicine regained full ownership of a series of CRISPR-based investigational drugs from AbbVie Inc. for treating eye diseases.
- In May 2020, Sherlock Biosciences received Emergency Use Authorization from the FDA for its Sherlock CRISPR SARS-CoV-2 kit, designed to detect the virus responsible for COVID-19.

The CRISPR and Cas gene market report is based on data from primary and secondary sources, including the US Food and Drug Administration, the Centers for Disease Control and Prevention (CDC), and the Global Burden of Disease Study.